Abstract
We report results of brachytherapy for carcinoma of the vagina, utilizing a NucletronTM high dose rate system for Delclos Vaginal Applicators (cylinder) and Syed Template Applicators (interstitial). The linear quadratic (LQ) model was used to determine the optimum time-dose-fractionation schedules. Interstitial doses were determined at the isodose line that included gross tumour. Cylinder doses were determined either at the vaginal surface (5 cases), at 0.5 cm depth (5 cases), or at 1.0 cm depth (1 case). For the first treatment (n=19), interstitial templates were utilized in 8 patients and vaginal cylinders in 11. 11 patients received second treatments: 6 templates and 5 cylinders. The median dose of external beam radiation (n=15) was 40.0 Gy followed, after a median 23 day interval, by high dose rate brachytherapy (HDRB) of 4 fractions in 30–42 h; then a median interval gap of 25 days, followed by repeat HDRB. The median total fractionated HDRB dose per patient was 23.0 Gy (range: 6.9 Gy to 40.4 Gy; calculated low dose rate equivalent of 29.8 Gy). Tumour histologies included 14 squamous cell carcinomas, 2 adenocarcinomas, 2 melanomas, and 1 small cell tumour. Three patients experienced early brachytherapy-related complications (diarrhoea, dysuria and labial dermatitis). Three patients (15.8%) developed serious/late complications including ureteral stenosis, painful vaginal necrosis and small bowel obstruction. The first of these patients received 2 templates, the second a cylinder followed by a template and a cylinder, and the third a single cylinder. The 2 year progression-free survival was 39.3% (median 15.7 months), while the 2 year overall survival was 66.1% (median 29.9 months). 192Ir afterloading HDRB is a feasible approach to women with vaginal cancer with acceptable toxicity and tumour response. Potential advantages include patient preference, outpatient cost-effectiveness in the case of cylinder technique, and no radiation exposure to hospital personnel. Long-term follow-up is needed to further assess late complications, and larger studies are needed to confirm our results.
References
1 Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23–47.
2 Delouche G, Gest J. Treatment of uterine cancer by Curietron. Nouv Presse Med 1974;3:597–600.
3 Fournier DV, Senf W, Kuttig H, Kubli F. Improvement of gynecologic radium therapy through the afterloading method using cesium 137. Strahlentherapie 1976;151:195–207.
4 Hope-Stone HF, Klevenhagen SC, Mantell BS, Morgan WY, Scholnick SA. Use of the Curietron at the London Hospital. Clin Radiol 1981;32:17–23.
5 Joslin CA, Smith CW, Mallik A. The treatment of cervix cancer using high activity 60 Co sources. Br J Radiol 1972;45:257–70.
6 Fleming P, Syed N, Neblett D, Puthawala A, George FW, Townsend D. Description of an afterloading Ir-192 interstitial-intracavitary technique in the treatment of carcinoma of the vagina. Obstet Gynecol 1980;55:525–30.
7 Thames H, Hendry J. Fractionation in radiotherapy. London, UK: Taylor & Francis, 1987.
8 Fowler J. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679–94.
9 Dale R. The use of small fraction numbers in high dose-rate gynaecological afterloading: some radiobiological considerations. Br J Radiol 1990;63:290–4.
10 Utley J, Von Essen C, Horn R, Moeller J. High-dose-rate afterloading brachytherapy in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1984;10:2259–63.
11 Stock RG, Mychalczak B, Armstrong JG, Curtin JP, Harrison LB. The importance of brachytherapy techniques in the management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1992;24:747–53.
12 Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1996;35:891–905.
13 Perez CA, Grigsby PW, Garipagaoglu M, Mutch DG, Lockett MA. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1999;44:37–45.
14 Gupta AK, Vicini FA, Frazier AJ, Barth-Jones DC, Edmundson GK, Mele E, et al. Iridium-192 transperineal interstitial brachytherapy for locally advanced or recurrent gynecological malignancies. Int J Radiat Oncol Biol Phys 1999;43:1055–60.
15 Nag S, Martinez-Monge R, Selman AE, Copeland LJ. Interstitial brachytherapy in the management of primary carcinoma of the cervix and vagina. Gynecol Oncol 1998;70:27–32.
16 MacLeod C, Fowler A, Dalrymple C, Atkinson K, Elliott P, Carter J. High-dose-rate brachytherapy in the management of high-grade intraepithelial neoplasia of the vagina. Gynecol Oncol 1997;65:74–7.
17 Ogino I, Kitamura T, Okajima H, Matsubara S. High-dose-rate intracavitary brachytherapy in the management of cervical and vaginal intraepithelial neoplasia. Int J Radiat Oncol Biol Phys 1998;40:881–7.
18 Xiang-E W, Shu-mo C, Ya-qin D, Ke W. Treatment of late recurrent vaginal malignancy after initial radiotherapy for carcinoma of the cervix: an analysis of 73 cases. Gynecol Oncol 1998;69:125–9.
19 Ito H, Shigematsu N, Kawada T, Kubo A, Isobe K, Hara R, et al. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol 1997;67:154–61.
20 Nanavati PJ, Fanning J, Hilgers RD, Hallstrom J, Crawford D. High-dose-rate brachytherapy in primary Stage I and II vaginal cancer. Gynecol Oncol 1993;51:67–71.
21 Kucera H, Mock U, Knocke TH, Kucera E, Potter R. Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. Acta Obstet Gynecol Scand 2001;80:355–60.
22 Dusenbery KE, Carson LF, Potish RA. Perioperative morbidity and mortality of gynecologic brachytherapy. Cancer 1991;67:2786–90.
23 Lee WR, Marcus RB, Sombeck MD, Mendenhall WM, Morgan LS, Freeman DE, et al. Radiotherapy alone for carcinoma of the vagina: the importance of overall treatment time. Int J Radiat Oncol Biol Phys 1994;29:983–8.
24 Demanes DJ, Rege S, Rodriquez RR, Schutz KL, Altieri GA, Wong T. The use and advantages of a multichannel vaginal cylinder in high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:211–9.
